Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
ConditionCDKL5
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-50
SponsorUniversity of Milan
About this trial
Standard anti-seizure medications have limited efficacy in seizure control in cyclin-dependent kinase-like 5 deficiency disorder (CDD).
The study will investigate whether targeting the gut-microbiota-brain axis in CDD patients can alleviate seizures and ameliorate other comorbidities.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- alpha-lactalbumin, fructooligosaccharides, inulin
- alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov